Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the
efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients
with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag
treatment.